Eli Lilly Acquires 4E Therapeutics to Strengthen Non-Opioid Pain Pipeline

Eli Lilly has acquired 4E Therapeutics, a neuroscience biotech developing non-opioid treatments for chronic pain. This marks Lilly’s 11th deal of 2026 and strengthens its non-opioid pain pipeline.